MA26431A1 - Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b - Google Patents

Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b

Info

Publication number
MA26431A1
MA26431A1 MA24630A MA24630A MA26431A1 MA 26431 A1 MA26431 A1 MA 26431A1 MA 24630 A MA24630 A MA 24630A MA 24630 A MA24630 A MA 24630A MA 26431 A1 MA26431 A1 MA 26431A1
Authority
MA
Morocco
Prior art keywords
preparation
treatment
mamifer
arylpyrimidines
medicaments
Prior art date
Application number
MA24630A
Other languages
English (en)
Inventor
Berger Jacob
Jaime-Figueroa Saul
George Putman David
Zhao Shu-Hai
Allen Flippin Lee
Greenhouse Robert
Liu Yanzhou
Kern Miller Aubry
Kurt Weinhardt Klaus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26431A1 publication Critical patent/MA26431A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA24630A 1996-05-23 1997-05-21 Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b MA26431A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1821896P 1996-05-23 1996-05-23
US4037797P 1997-03-10 1997-03-10

Publications (1)

Publication Number Publication Date
MA26431A1 true MA26431A1 (fr) 2004-12-20

Family

ID=26690869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24630A MA26431A1 (fr) 1996-05-23 1997-05-21 Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b

Country Status (31)

Country Link
US (1) US5863924A (fr)
EP (1) EP0901474B1 (fr)
JP (1) JP2001525794A (fr)
KR (1) KR100518101B1 (fr)
CN (1) CN1109675C (fr)
AR (1) AR007253A1 (fr)
AT (1) ATE323682T1 (fr)
AU (1) AU725891B2 (fr)
BR (1) BR9709599A (fr)
CA (1) CA2255705A1 (fr)
CO (1) CO4950514A1 (fr)
CZ (1) CZ291849B6 (fr)
DE (1) DE69735712T2 (fr)
DK (1) DK0901474T3 (fr)
ES (1) ES2262178T3 (fr)
HR (1) HRP970275B1 (fr)
HU (1) HUP9901535A3 (fr)
ID (1) ID16969A (fr)
IL (1) IL127056A (fr)
MA (1) MA26431A1 (fr)
MY (1) MY119181A (fr)
NO (1) NO311800B1 (fr)
NZ (1) NZ332802A (fr)
PT (1) PT901474E (fr)
RU (1) RU2189976C2 (fr)
SA (2) SA05260356B1 (fr)
TR (1) TR199802391T2 (fr)
TW (1) TW440563B (fr)
UY (1) UY24560A1 (fr)
WO (1) WO1997044326A1 (fr)
YU (1) YU53298A (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011643A1 (fr) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Pyridines a cycle fusionne et a substitution heterocyclyle, antagonistes du facteur de liberation de la cortitropine (crf), utiles dans le traitement des troubles lies au snc et au stress
US6040315A (en) * 1997-10-30 2000-03-21 Day; Charles E. Antacid co-polymer of guanidine and polyethylenimine
DE19844291A1 (de) * 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2359680A1 (fr) * 1999-01-22 2000-07-27 David M. Armistead Inhibiteurs de kinase
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
ES2226647T3 (es) 1999-05-26 2005-04-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de vinil pirimidina.
DE60005526T2 (de) * 1999-07-30 2004-07-01 Pharmagene Laboratories Ltd. Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
YU63802A (sh) * 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US6444477B1 (en) 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002092090A1 (fr) * 2001-05-14 2002-11-21 Bristol-Myers Squibb Pharma Company Pyrazinones, pyridines et pyrimidines substitues en tant que ligands de la corticoliberine
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
CA2450934A1 (fr) * 2001-06-19 2002-12-27 Marco Dodier Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
EP1474141A1 (fr) * 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd Antagonistes du recepteur 5-ht2b
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (fr) 2002-03-09 2003-09-18 Astrazeneca Ab Derives de la pyrimidine substituee par 4-imidazolyle presentant une activite d'inhibition de cdk
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
US20040023978A1 (en) * 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
IL166241A0 (en) * 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
SI1625121T1 (sl) * 2002-12-20 2010-04-30 Pfizer Prod Inc Derivati pirimidina za zdravljenje abnormalne rasti celic
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
KR20060052806A (ko) * 2003-07-25 2006-05-19 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 항균제로서 치환된 2,4-비스(알킬아미노)피리미딘 또는-퀴나졸린의 용도
ES2421139T3 (es) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
JP2007519754A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
CA2557158A1 (fr) 2004-02-20 2005-09-01 Astellas Pharma Inc. Agents prophylactiques contre la migraine
JP2007532669A (ja) * 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
EP1758887A1 (fr) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1805142A4 (fr) * 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc Composes a base de pyridine, leur procede de preparation et compositions les contenant
ATE520672T1 (de) * 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7935711B2 (en) * 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CN101151249B (zh) * 2005-03-31 2011-04-06 辉瑞产品公司 环戊吡啶及四氢喹啉衍生物
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
BRPI0616575A2 (pt) * 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
AU2006296386A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
US20080293942A1 (en) * 2005-11-28 2008-11-27 Cousins Russell D Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives
WO2007097276A1 (fr) 2006-02-20 2007-08-30 Astellas Pharma Inc. Dérivé de pyrrole ou sel de celui-ci
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
EP2094681A1 (fr) * 2006-12-22 2009-09-02 Novartis AG Dérivés d'indol-4-yl-pyrimidinyl-2-yl-amine et leur utilisation comme inhibiteurs de la kinase dépendante des cyclines
PE20090110A1 (es) 2007-03-01 2009-04-04 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
AU2008289037B2 (en) * 2007-08-22 2012-03-01 Novartis Ag 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
RU2378278C2 (ru) * 2008-01-24 2010-01-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
MX2010009110A (es) 2008-02-19 2010-11-30 Adolor Corp Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor.
AU2008355098B2 (en) 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
PE20120325A1 (es) * 2009-05-19 2012-04-12 Dow Agrosciences Llc Aminopirimidinas sustituidas con arilo como agentes fungicidas
CA2788450A1 (fr) 2009-12-30 2011-07-07 Arqule, Inc. Composes naphthalenyl-pyrimidine substitues
CN102786512A (zh) * 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
EP3154547B1 (fr) 2014-06-13 2023-06-07 Yuma Therapeutics, Inc. Composés pyrimidiques et procédés les utilisant
CN104725322B (zh) * 2015-02-16 2017-05-24 同济大学 一种2‑胺基嘧啶类化合物及其制备方法
CN107614503B (zh) * 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
RU2605265C1 (ru) * 2015-10-06 2016-12-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Анальгезирующее и противовоспалительное средство на основе 5-бутил-6-гидрокси-2-метилпиримидин-4(3h)-она
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
CN108904503B (zh) * 2018-07-02 2021-09-28 陕西科技大学 6-氯-5-硝基-2,4-二氨基嘧啶在治疗慢性粒细胞白血病药物中的应用
BR112021022538A2 (pt) * 2019-06-06 2021-12-28 Arcus Biosciences Inc Processos para preparar compostos de aminopirimidina
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
CN114907273B (zh) * 2022-06-09 2025-02-18 乐威医药（江苏）股份有限公司 2-氨基嘧啶-6-芳基化合物的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) * 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
US3965101A (en) * 1973-07-26 1976-06-22 E. R. Squibb & Sons, Inc. 1-(O-Bromo-phenoxyalkyl)-1,2-dihydro-2-iminopyrimidines
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4543248A (en) * 1979-03-19 1985-09-24 The Upjohn Company Method for immunoregulation with 6-aryl pyrimidine compounds
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US5002951A (en) * 1979-03-19 1991-03-26 The Upjohn Company Method for treating bacterial and protozoal infections
DE3029871C2 (de) * 1979-08-08 1987-01-15 G.D. Searle & Co., Skokie, Ill. 8-(2-Ethoxyethyl)-7-phenyl-1,2,4-triazolo[1,5-c]pyrimidin-5-amin, Verfahren zu dessen Herstellung und pharmazeutische Zubereitung, die diese Verbindung enthält
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
FR2539741A1 (fr) * 1983-01-21 1984-07-27 Sanofi Sa Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
US4512993A (en) * 1983-07-25 1985-04-23 Sterling Drug Inc. 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof
US4504482A (en) * 1983-07-28 1985-03-12 Sterling Drug Inc. [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof
EP0210228A1 (fr) * 1985-02-05 1987-02-04 The Upjohn Company Composes de 4-substitue-6-aryl-pyrimidine
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
EP0310550B1 (fr) * 1987-09-28 1993-05-26 Ciba-Geigy Ag Produit antiparasite
WO1989005295A1 (fr) * 1987-12-02 1989-06-15 Pfizer Inc. Derives acyle d'hydroxypyrimidines
US4929726A (en) * 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
WO1989011279A1 (fr) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Compose heteropolycyclique non fusionne ayant une interaction avec des acides nucleiques
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
IE63502B1 (en) * 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE4237768A1 (en) * 1991-11-12 1993-05-13 Ciba Geigy Ag New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives
US5698444A (en) * 1993-12-23 1997-12-16 Eli Lilly And Company Serotonin receptor protein and related nucleic acid compounds
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
US5786355A (en) * 1995-04-13 1998-07-28 Taiho Pharmaceutical Co., Ltd. 4,6-diarylpyrimidine derivatives and salts thereof
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto

Also Published As

Publication number Publication date
HK1020345A1 (en) 2000-04-14
MY119181A (en) 2005-04-30
AU725891B2 (en) 2000-10-26
SA97180191B1 (ar) 2006-03-15
HUP9901535A2 (hu) 1999-09-28
UY24560A1 (es) 2000-12-29
HRP970275A2 (en) 1998-04-30
AR007253A1 (es) 1999-10-27
NZ332802A (en) 2000-07-28
JP2001525794A (ja) 2001-12-11
ATE323682T1 (de) 2006-05-15
CN1223641A (zh) 1999-07-21
ID16969A (id) 1997-11-27
CZ380398A3 (cs) 1999-04-14
CZ291849B6 (cs) 2003-06-18
DE69735712D1 (de) 2006-05-24
US5863924A (en) 1999-01-26
KR100518101B1 (ko) 2005-12-26
DK0901474T3 (da) 2006-07-31
EP0901474B1 (fr) 2006-04-19
SA05260356B1 (ar) 2006-04-25
NO985392D0 (no) 1998-11-19
NO311800B1 (no) 2002-01-28
ES2262178T3 (es) 2006-11-16
YU53298A (en) 1999-11-22
KR20000015900A (ko) 2000-03-15
HRP970275B1 (en) 2002-12-31
RU2189976C2 (ru) 2002-09-27
DE69735712T2 (de) 2006-11-30
AU2897897A (en) 1997-12-09
TR199802391T2 (xx) 1999-02-22
NO985392L (no) 1999-01-25
CA2255705A1 (fr) 1997-11-27
HUP9901535A3 (en) 2002-07-29
TW440563B (en) 2001-06-16
PT901474E (pt) 2006-07-31
IL127056A (en) 2003-11-23
WO1997044326A1 (fr) 1997-11-27
EP0901474A1 (fr) 1999-03-17
IL127056A0 (en) 1999-09-22
BR9709599A (pt) 1999-08-10
CN1109675C (zh) 2003-05-28
CO4950514A1 (es) 2000-09-01

Similar Documents

Publication Publication Date Title
HUP9903654A3 (en) Biconvex rapidly disintegrating dosage forms
MA22668A1 (fr) Procede de preparation d'oxamides .
EP0686203A4 (fr) Composes et procedes concernant le diagnostic, le traitement et la prevention de maladies dues a la mort de cellules
FR2692586B1 (fr) Granules, procede pour les preparer et leur utilisation.
DE69428357D1 (de) Vorrichtung zur behandlung des diabetes mellitus
DE69013249D1 (de) Fluorelastomere mit verbesserter Verarbeitbarkeit und Verfahren zu ihrer Herstellung.
FR2660556B1 (fr) Microspheres, leur procede de preparation et leur utilisation.
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
DE69203755D1 (de) Kernbrennstofftabletten und Verfahren zur Herstellung derselben.
FR2668389B1 (fr) Procede de traitement antipollution d'un catalyseur de raffinage a l'etat use et recuperation des metaux.
BE896830A (fr) Procede de preparation du 26, 26, 26, 27, 27, 27-hexafluoro-1 alpha, 25-dihydroxycholesterol.
MA22649A1 (fr) Procede de preparation de composes pour le traitement des maladies en rapport avec le leucotriene .
BE874198A (fr) Procede de conservation a l'etat frais d'herbes aromatiques et compositions d'herbes ainsi obtenues.
FR2668938B1 (fr) Nouveau procede de traitement antipollution d'un catalyseur de raffinage a l'etat use et recuperation total des differents constituants metalliques dudit catalyseur.
MA23953A1 (fr) Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites
MA24239A1 (fr) Melange comprenant de la virginiamycine, procede pour sa preparation et traitement de denrees avec ce melange
DE69007435D1 (de) Vorrichtung zum Zerkleinern und Dispergieren.
TR199501611A1 (tr) Sameridin'in hazirlanmasi icin yeni proses.
FR2788523B1 (fr) Derives de calixarenes, leur procede de preparation et leur utilisation pour l'extraction des actinides et des lanthanides
FR2786487B1 (fr) Derives de calixarenes, leur procede de preparation et leur utilisation pour l'extraction des actinides et des lanthanides
FR2725450B1 (fr) Aminoplastes, procede pour leur preparation et leur utilisation
FR2679229B1 (fr) Procede de preparation du cis-inositol, du meso-inositol, de l'epi-inositol et/ou du cis-quercitol eventuellement deuteres.
IL98098A0 (en) Low fat,low cholesterol process cheeses and methods for the manufacture thereof
GR3020295T3 (en) Substituted pyridazinones, process for their preparation and their use as parasiticide
DE3268585D1 (en) N-substituted o-pyrazol-4-yl-carbamic-acid esters, process for their preparation and their use as biocides